228 related articles for article (PubMed ID: 28745322)
1. p53 loss does not permit escape from Braf
Garnett S; Dutchak KL; McDonough RV; Dankort D
Oncogene; 2017 Nov; 36(45):6325-6335. PubMed ID: 28745322
[TBL] [Abstract][Full Text] [Related]
2. TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
Shai A; Dankort D; Juan J; Green S; McMahon M
Cancer Res; 2015 Aug; 75(15):3167-80. PubMed ID: 26001956
[TBL] [Abstract][Full Text] [Related]
3. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M
Genes Dev; 2007 Feb; 21(4):379-84. PubMed ID: 17299132
[TBL] [Abstract][Full Text] [Related]
4. Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas.
González-Sánchez E; Martín-Caballero J; Flores JM; Hernández-Losa J; ; Cortés J; Mares R; Barbacid M; Recio JA
PLoS One; 2013; 8(6):e66933. PubMed ID: 23825589
[TBL] [Abstract][Full Text] [Related]
5. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence.
Tabor V; Bocci M; Alikhani N; Kuiper R; Larsson LG
Cancer Res; 2014 Aug; 74(16):4222-9. PubMed ID: 24934810
[TBL] [Abstract][Full Text] [Related]
6. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
[TBL] [Abstract][Full Text] [Related]
7. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
8. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
[TBL] [Abstract][Full Text] [Related]
10. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
11. Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors.
Juan J; Muraguchi T; Iezza G; Sears RC; McMahon M
Genes Dev; 2014 Mar; 28(6):561-75. PubMed ID: 24589553
[TBL] [Abstract][Full Text] [Related]
12. A Braf kinase-inactive mutant induces lung adenocarcinoma.
Nieto P; Ambrogio C; Esteban-Burgos L; Gómez-López G; Blasco MT; Yao Z; Marais R; Rosen N; Chiarle R; Pisano DG; Barbacid M; Santamaría D
Nature; 2017 Aug; 548(7666):239-243. PubMed ID: 28783725
[TBL] [Abstract][Full Text] [Related]
13. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
[TBL] [Abstract][Full Text] [Related]
14. Early differential responses elicited by BRAF
Bosso G; Lanuza-Gracia P; Piñeiro-Hermida S; Yilmaz M; Serrano R; Blasco MA
Cell Death Dis; 2022 Feb; 13(2):142. PubMed ID: 35145078
[TBL] [Abstract][Full Text] [Related]
15. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
[TBL] [Abstract][Full Text] [Related]
16. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
17. Overcoming resistance in a
Schmid T; Buess M
Curr Oncol; 2018 Jun; 25(3):e217-e219. PubMed ID: 29962848
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
Peng S; Sen B; Mazumdar T; Byers LA; Diao L; Wang J; Tong P; Giri U; Heymach JV; Kadara HN; Johnson FM
Oncotarget; 2016 Jan; 7(1):565-79. PubMed ID: 26623721
[TBL] [Abstract][Full Text] [Related]
19. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
